Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer

about

Alterations of Signaling Pathways Related to the Immune System in Breast Cancer: New Perspectives in Patient Management

P2860

Q57106000-BEC4B52A-9DE6-4D54-AD42-EDA08FC2494B

P2860

Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer

Item

http://www.wikidata.org/entity/Q35803370

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Clinical efficacy of administe ...... triple-negative breast cancer

@ast

Clinical efficacy of administe ...... triple-negative breast cancer

@en

type

Item

label

Clinical efficacy of administe ...... triple-negative breast cancer

@ast

Clinical efficacy of administe ...... triple-negative breast cancer

@en

prefLabel

Clinical efficacy of administe ...... triple-negative breast cancer

@ast

Clinical efficacy of administe ...... triple-negative breast cancer

@en

P1476

Clinical efficacy of administe ...... triple-negative breast cancer

@en

P2093

Jian-Xiong Guo

http://www.w3.org/2001/XMLSchema#string

Juan Zhou

http://www.w3.org/2001/XMLSchema#string

Jun Liu

http://www.w3.org/2001/XMLSchema#string

Rong-Xia Zhang

http://www.w3.org/2001/XMLSchema#string

Wei Wei

http://www.w3.org/2001/XMLSchema#string

Xiao-Hong Huang

http://www.w3.org/2001/XMLSchema#string

Yang Xiao

http://www.w3.org/2001/XMLSchema#string

Yang-Chen Liu

http://www.w3.org/2001/XMLSchema#string

Yi-Jia Wu

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Molecular portraits of human breast tumours

Hallmarks of 'BRCAness' in sporadic cancers

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.

[Chemotherapy of a 2-week S-1 administration followed by 1-week rest for advanced and metastatic breast cancer].

A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338.

Efficacy and safety of docetaxel combined with oxaliplatin as a neoadjuvant chemotherapy regimen for Chinese triple-negative local advanced breast cancer patients. A prospective, open, and unicentric Phase II clinical trial.

S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis.

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

P304

379-385

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/ETM.2015.2489

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276463319

http://www.w3.org/2001/XMLSchema#string

P698

26170966

http://www.w3.org/2001/XMLSchema#string

P932

4487007

http://www.w3.org/2001/XMLSchema#string

Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer

about

P2860

P2860

Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932